DIET AND THE RISK OF INVASIVE CERVICAL CANCER AMONG WHITE WOMEN IN THE UNITED STATES

1990 ◽  
Vol 132 (3) ◽  
pp. 432-445 ◽  
Author(s):  
REGINA G. ZIEGLER ◽  
LOUISE A. BRINTON ◽  
RICHARD F. HAMMAN ◽  
HERMAN F. LEHMAN ◽  
ROBERT S. LEVINE ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
White Women ◽  
Invasive Cervical Cancer ◽  
The United States

Utilization of Diagnostic Studies in the Pretreatment Evaluation of Invasive Cervical Cancer in the United States: Results of Intergroup Protocol ACRIN 6651/GOG 183

2005 ◽  
Vol 23 (30) ◽  
pp. 7454-7459 ◽  
Author(s):  
Marco A. Amendola ◽  
Hedvig Hricak ◽  
Donald G. Mitchell ◽  
Bradley Snyder ◽  
Dennis S. Chi ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Data Analysis ◽  
Diagnostic Tests ◽  
Gynecologic Oncology ◽  
Invasive Cervical Cancer ◽  
The United States ◽  
Patterns Of Care ◽  
Clinical Staging ◽  
Gynecologic Oncology Group

Purpose To review the current utilization of diagnostic tests prescribed by the International Federation of Gynecology and Obstetrics (FIGO) clinical staging guidelines in the pretreatment work-up of invasive cervical cancer, and to compare the data with those of previous patterns of care studies. Patients and Methods This interdisciplinary American College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial was conducted between March 1, 2000, and November 11, 2002. Twenty-five participating institutions, all from the United States, enrolled a total of 208 patients. Only patients scheduled for surgery with biopsy-confirmed cervical cancer of clinical FIGO stage IB or higher were eligible. The patterns of care data analysis was based on 197 patients who met all inclusion criteria. The conventional FIGO-recommended tests used for pre-enrollment FIGO clinical stage classification were at the discretion of the treating physician; overall frequency of use was tabulated for each test. Results Use of cystoscopy (8.1%) and sigmoidoscopy or proctoscopy (8.6%) was significantly lower than in 1988 to 1989 (P < .0001 in each instance). Intravenous urography was used in only 1% of patients as compared with 42% in 1988 to 1989 and 91% in 1983. No patient included in the data analysis had barium enema or lymphangiography. Only 26.9% of patients had examination under anesthesia for FIGO clinical staging. Conclusion There is a large discrepancy between the diagnostic tests recommended by FIGO and the actual tests used for cervical cancer staging, suggesting a need to reassess the relevance of the FIGO guidelines to current clinical practice in the United States.

Diet and the risk of in situ cervical cancer among white women in the United States

1991 ◽  
Vol 2 (1) ◽  
pp. 17-29 ◽  
Author(s):  
Regina G. Ziegler ◽  
Carol J. Jones ◽  
Louise A. Brinton ◽  
Sandra A. Norman ◽  
Katherine Mallin ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
White Women ◽  
The United States

Higher incidence and mortality rates of cervical cancer in African-American women in Louisiana.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17522-e17522
Author(s):  
Genevieve Folse Maronge ◽  
Xiao-cheng Wu ◽  
Vivien Chen ◽  
Xiangrong Li ◽  
Brian C. Boulmay ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
African American Women ◽  
Hpv Vaccine ◽  
White Women ◽  
The United States ◽  
Mortality Rates ◽  
Hospital System ◽  
Incidence And Mortality ◽  
The Us

e17522 Background: Cervical cancer [CC] incidence in the United States has decreased over the last thirty years in black and white Americans, however it is recognized that black women [BW] have higher incidence and mortality rates than white women [WW]. We evaluated race-specific incidence of CC, mortality rates of CC, and HPV vaccine usage rates in Louisiana [LA] during the last decade, the state with the second highest proportion of black Americans in the United States [US]. Methods: Data from Surveillance, Epidemiology, and End Results (SEER) registries were analyzed for trends in incidence and mortality rate [MR] in BW and WW in LA and the US. SEER 13 and SEER 18 data were used and standardized to the 2000 US population to estimate annual age-adjusted incidence and mortality rates. Results: The incidence of CC in WW in LA was 8.2 per 100,000 from 2006 to 2009, and 7.9 per 100,000 in WW in US. The incidence in BW in LA was 13.3 per 100,000, as compared to the US at 9.7 per 100,000, a 36% higher incidence in BW. The MR in WW in LA and the US was 2.4 and 2.2 per 100,000. The MR for BW in LA was 5.8 per 100,000 and the US was 4.3 per 100,000, a 37% higher incidence in BW. WW in LA and the US showed a peak in incidence between the ages of 35 and 45 from 2006 to 2009. The incidence in BW in LA peaked at 37.1 per 100,000 at age 85 and the incidence in BW in the US peaked at 25.6 per 100,000 at age 85. HPV vaccination rates for LA females ages 13-15 in 2008 and 2009 were 16.1% and 35.4%. Conclusions: BW in LA were twice as likely to be diagnosed with CC than WW with a higher MR. Though the incidence rate of CC is decreasing in WW and BW in the US and in WW in LA, it is increasing in BW in LA and continues to trend up throughout life in BW compared to WW. The high incidence of CC in BW in LA highlights the need to improve utilization of the HPV vaccine. A screening and treatment program targeting CC was implemented within the last decade in the LA public hospital system with the goal of reducing CC incidence and mortality.

Impact of NCI Clinical Announcement upon use of chemoradiation for women with cervical cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5537-5537 ◽  
Author(s):  
E. L. Trimble ◽  
D. Gius ◽  
L. C. Harlan
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Invasive Cervical Cancer ◽  
The United States ◽  
Initial Therapy ◽  
Population Based ◽  
Phase Iii ◽  
Younger Women ◽  
Platinum Based Chemotherapy ◽  
To Receive

5537 Background: On the basis of 5 NCI-sponsored randomized phase III trials, in 1999 the NCI issued a Clinical Announcement recommending that women with cervical cancer who require radiation also receive concomitant platinum-based chemotherapy. We undertook a population-based cohort study to determine whether the 1999 NCI Clinical Announcement was associated with changes in clinical practice in the United States. Methods: Through the NCI’s SEER program, we identified 973 women with invasive cervical cancer diagnosed in 1997, 773 diagnosed in 2000, and 1370 diagnosed in 2001. Hospital records were re-abstracted and treated physicians were contacted to verify initial therapy provided to each patient. Results: In multivariate analysis, we found a significant increase in the use of chemoradiation between 1997 and 2001/2001 among women with cervical cancer of all stages for which radiation would be appropriate. (see table ). Compared to women with well-differentiated tumors, women with moderately or poorly differentiated tumors were more likely to receive chemoradiation. Women aged 75 years or older were significantly less likely to receive chemoradiation than younger women. We saw no impact of race/ ethnicity or insurance status upon receipt of chemoradiation. Conclusions: Publication of the results from these 5 sutdies, extensive professional educational efforts, and the NCI’s Clinical Announcement were associated with widespread adoption of chemotherapy in the treatment of cervical cancer in the United States. [Table: see text] No significant financial relationships to disclose.

Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity

2009 ◽  
Vol 20 (7) ◽  
pp. 1129-1138 ◽  
Author(s):  
Jill Barnholtz-Sloan ◽  
Nitin Patel ◽  
Dana Rollison ◽  
Karl Kortepeter ◽  
Jill MacKinnon ◽  
...  
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Race And Ethnicity ◽  
Invasive Cervical Cancer ◽  
The United States ◽  
Incidence Trends
Sign in / Sign up

Export Citation Format

Share Document